Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01699061 · ClinicalTrials.gov registry record · Phase 1
Effect of Tivantinib on the QTC Interval in Cancer Subjects
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT01699061 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 38 participants.
The verdict
NCT01699061, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of tivantinib on the QTc interval in patients with solid tumors
Interventions
- DRUG Placebo
- DRUG Tivantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01699061
The ClinicalTrials.gov registry entry for NCT01699061 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01699061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01699061 about?
NCT01699061 is a clinical study titled "Effect of Tivantinib on the QTC Interval in Cancer Subjects". The purpose of this study is to determine the effects of tivantinib on the QTc interval in patients with solid tumors
What is the current status of trial NCT01699061?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2012-07. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01699061?
The interventions under investigation include: Placebo (DRUG), Tivantinib (DRUG).
Who is sponsoring clinical trial NCT01699061?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.